Literature DB >> 15383564

Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma.

Yasuharu Akasaki1, Gentao Liu, Nancy H C Chung, Moneeb Ehtesham, Keith L Black, John S Yu.   

Abstract

PGE(2), synthesized by cyclooxygenase-2 (COX-2)-overexpressing tumor, is known to contribute to cellular immune suppression in cancer patients, but the mechanism remains unclear. We report the mechanism of a CD4(+) T regulatory type 1 (Tr1) induction by CD11c(+) mature dendritic cells (DCs) that phagocytose allogeneic and autologous COX-2-overexpressing glioma. A human glioma cell line, U-87MG, and primary cultured glioblastoma cells (MG-377) overexpressed COX-2. We did not detect IL-10Ralpha expression in these gliomas, and rIL-10 did not suppress their COX-2 expression. Exposure to COX-2-overexpressing glioma induced mature DCs to overexpress IL-10 and decreased IL-12p70 production. These DCs induced a Tr1 response, which is characterized by robust secretion of IL-10 and TGF-beta with negligible IL-4 secretion by CD4(+) T cells, and an inhibitory effect on admixed lymphocytes. Peripheral CD4(+) T cell populations isolated from an MG-377 patient also predominantly demonstrated a Tr1 response against MG-377 cells. Selective COX-2 inhibition in COX-2-overexpressing gliomas at the time of phagocytic uptake by DCs abrogated this regulatory response and instead elicited Th1 activity. COX-2 stable transfectants in LN-18 (LN-18-COX2) also induced a Tr1 response. The effect of a COX-2 inhibition in LN-18-COX2 is reversible after administration of PGE(2). Taken together, robust levels of PGE(2) from COX-2-overexpressing glioma, which is unresponsive to IL-10 within the local microenvironment, may cause DCs to secrete high levels of IL-10. These results indicate that COX-2-overexpressing tumors induce a Tr1 response, which is mediated by tumor-exposed, IL-10-enhanced DCs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383564     DOI: 10.4049/jimmunol.173.7.4352

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Neurochem Res       Date:  2007-08-04       Impact factor: 3.996

2.  Fascin-1 knock-down of human glioma cells reduces their microvilli/filopodia while improving their susceptibility to lymphocyte-mediated cytotoxicity.

Authors:  Neil T Hoa; Lisheng Ge; Kate L Erickson; Carol A Kruse; Andrew N Cornforth; Yurii Kuznetsov; Alex McPherson; Filippo Martini; Martin R Jadus
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

4.  Prostaglandin E2 Inhibition of IL-27 Production in Murine Dendritic Cells: A Novel Mechanism That Involves IRF1.

Authors:  Kirsten M Hooper; Jui-Hung Yen; Weimin Kong; Kate M Rahbari; Ping-Chang Kuo; Ana M Gamero; Doina Ganea
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

Review 5.  TGFβ in T cell biology and tumor immunity: Angel or devil?

Authors:  Eric Tu; Pei Zhi Cheryl Chia; Wanjun Chen
Journal:  Cytokine Growth Factor Rev       Date:  2014-07-29       Impact factor: 7.638

6.  Gene expression profiles in granuloma tissue reveal novel diagnostic markers in sarcoidosis.

Authors:  George P Christophi; Tiffany Caza; Christopher Curtiss; Divya Gumber; Paul T Massa; Steve K Landas
Journal:  Exp Mol Pathol       Date:  2014-04-21       Impact factor: 3.362

7.  Clinical and immunomodulatory effects of celecoxib plus interferon-alpha in metastatic renal cell carcinoma patients with COX-2 tumor immunostaining.

Authors:  Anita Schwandt; Jorge A Garcia; Paul Elson; Jeanie Wyckhouse; James H Finke; Joanna Ireland; Pierre Triozzi; Ming Zhou; Robert Dreicer; Brian I Rini
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

8.  The role of STAT3 activation in modulating the immune microenvironment of GBM.

Authors:  Alfred P See; James E Han; Jillian Phallen; Zev Binder; Gary Gallia; Fan Pan; Dilini Jinasena; Christopher Jackson; Zineb Belcaid; Sung Jin Jeong; Chelsea Gottschalk; Jing Zeng; Jacob Ruzevick; Sarah Nicholas; Young Kim; Emilia Albesiano; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

Review 9.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 10.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Authors:  William Humphries; Jun Wei; John H Sampson; Amy B Heimberger
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.